Previous research has shown that both MRPL15 and MRPS23 can be selected as companion diagnostics, to decide which breast cancer patients might benefit most from clinical therapy (Sotgia, Fiorillo & Lisanti, 2017). Here, MRPS23 is linked to breast cancer.